The Prospectus Supplement, dated January 30, 2009 contains a very deatailed discussion of the 3 1/2 year patent dispute issues. So far, Abbott Diabetes Care has repeatedly struck out. If Dexcom is successful in obtaining a final rejection of Abbott's claims, this stock is going to explode higher like a rocket. The overhang from this litigation has to be in the neighborhood of $2-$3 a share.
Although not final, this sure sounds encouraging:
"In early 2008, the Patent Office issued a non-final rejection of all claims we have submitted for reexamination in the other two patents cited in the original complaint." -from the Prospectus Filing